Substantial genetic, variability for grain protein content in wheat has been identified. In appropriate combinations known genes can increase protein content of wheat grain by 5 percentage points. Productive high protein experimental lines with good agronomic traits and satisfactory processing attributes have been identified. A high protein hard red winter variety developed in Nebraska was released for commercial production in 1975 under the name "Lancota". The high protein of Lancota resides entirely in the starchy endosperm portion of the kernel and is fully transmissible to white milled flour. The high protein of Lancota results from elevated NO3 reductase activity, increased N-absorption by the roots, and more complete translocation of N to the grain. Despite strong environmental influence on wheat protein level, genes for high protein have been demonstrated to effectively increase protein content in many different production environments. Lysine % of protein decreases but lysine % of grain increases as protein is increased. Genetic variability for lysine of sufficient magnitude to overcome the normal depression of lysine % of protein as protein is increased has been uncovered. Experimental lines have been developed in the ARS-Nebraska program in which genes for high protein and high lysine were combined. The lines have been widely distributed for use in other breeding programs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/978-1-4684-3366-1_16 | DOI Listing |
Comb Chem High Throughput Screen
January 2025
Department of Orthopedics, Hanzhong People's Hospital, Hanzhong, 723000, China.
Background: Rheumatoid Arthritis (RA), a chronic inflammatory autoimmune illness, is characterized by synovitis, progressive joint damage, and bone erosion. Even though the potent drugs available contain biologics, several patients fail to react to them or cause hostile effects.
Objectives: Betanin (BTN), the betacyanin present in the red beetroot, has antioxidant, antiinflammatory, and apoptotic properties.
Comb Chem High Throughput Screen
January 2025
Department of Nephrology, the First Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Shijiazhuang 050011,China.
Background: Shengyang Yiwei Decoction showed efficacy in idiopathic membranous nephropathy treatment, and this study aimed to assess the underlying molecular mechanisms.
Methods: Rats with passive Heymann nephritis were divided into the model group, the Shengyang Yiwei Decoction group, the JAK2 inhibitor group, and the STAT3 inhibitor group. Healthy rats served as the normal control.
Comb Chem High Throughput Screen
January 2025
Baoying People's Hospital, Yangzhou 225800, China.
Shuanghuanglian (SHL) and its primary constituents have demonstrated protective effects against allergenic diseases. This review examines the anaphylactic and anti-allergenic activities of SHL and its constituents. We also discuss potential avenues for future research, particularly regarding the expansion of the clinical applications of SHL formulations (oral or nebulized) for the treatment of allergenic disorders.
View Article and Find Full Text PDFEndocr Metab Immune Disord Drug Targets
January 2025
Department of Laboratory Medicine, Taizhou First People's Hospital, Huangyan Hospital of Wenzhou Medical University, Taizhou, Zhejiang, China.
Aim: The aim of this study is to examine the role of the microrchidia (MORC) family, a group of chromatin remodeling proteins, as the therapeutic and prognostic markers for colorectal cancer (CRC).
Background: MORC protein family genes are a highly conserved nucleoprotein superfamily whose members share a common domain but have distinct biological functions. Previous studies have analyzed the roles of MORCs as epigenetic regulators and chromatin remodulators; however, the involvement of MORCs in the development and pathogenesis of CRC was less examined.
J Pathol
January 2025
Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, MD, USA.
Rhabdomyosarcoma (RMS) is a family of phenotypically myogenic paediatric cancers consisting of two major subtypes: fusion-positive (FP) RMS, most commonly involving the PAX3::FOXO1 fusion gene, formed by the fusion of paired box 3 (PAX3) and forkhead box O1 (FOXO1) genes, and fusion-negative (FN) RMS, lacking these gene fusions. In humans, DNA methylation patterns distinguish these two subtypes as well as mutation-associated subsets within these subtypes. To investigate the biological factors responsible for these methylation differences, we profiled DNA methylation in RMS tumours derived from genetically engineered mouse models (GEMMs) in which various driver mutations were introduced into different myogenic lineages.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!